Interleukin-2 with its alpha Receptor

• Cat.No.: CBCRY33

Specification

• Cat. No.: CBCRY33
• Background: Interleukin-2 (IL-2) is an immunoregulatory cytokine that binds sequentially to the alpha (IL-2Ralpha), beta (IL-2Rbeta), and common gamma chain (gammac) receptor subunits.
• Protein Classification: Immune System
• Structure Weight: 40207.9 Da
• Polymer: 1
• Molecule: Interleukin-2
• Chain Length: 133 amino acids
• PDB ID: 1Z92
• MMDB ID: 33820
• Source: E.coli
• Method: X-Ray Diffraction
• Resolution: 2.80 Å
• Reference: Rickert, M., Wang, X., Boulanger, M.J., Goriatcheva, N., Garcia, K.C. (2005) The structure of interleukin-2 complexed with its alpha receptor. Science 308: 1477-1480
• Tag: Non

Gene Information

• Gene Name: IL2
• Synonyms: IL-2; TCGF; lymphokine; T cell growth factor; aldesleukin; interleukin-2; involved in regulation of T-cell clonal expansion; Aldesleukin
• UniProt ID: P60568
• Chromosome Location: 4q26-q27
• Function: cytokine activity; interleukin-2 receptor binding; protein binding; growth factor activity; kinase activator activity
• Gene ID: 3558

Reviews

09/29/2022

Security is very high and can be used with confidence.

06/05/2021

Structure is very stable and not prone to mutation.

03/14/2019

The amount of expression is very high and can be easily detected.

Q&As

Is there any adverse effect of IL2RA combined with other drugs?

The combination of IL2RA and other drugs may produce nausea, vomiting, rash and other adverse reactions, should be monitored.

How often is IL2RA used?

The frequency of use of IL2RA depends on the specific situation of the patient, and is generally used 1-3 times per week.

Whether there is an effect of IL2RA?

IL2RA, in the right dosage and frequency of use, can significantly relieve symptoms of diseases such as autoimmune diseases and organ transplant rejection.

Can IL2RA treat cancer?

Can assist in the treatment of some types of malignant tumors, but it is not a complete cure for cancer.

How effective is IL2RA treatment?

The effective rate of IL2RA therapy depends on many factors such as the type of disease, the patient's condition and the treatment regimen, and the effective rate is generally between 50% and 90%.

What are the indications for IL2RA?

Indications of IL2RA include a variety of autoimmune diseases, organ transplant rejection and malignant tumors.